Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Jul 18 2016

• By Derrick Gingery

Related Content

Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries

Jan 12 2015

Orphan Designation Requests To Get Slower US FDA Reviews

May 12 2016

FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Oct 27 2014

PDUFA Commitment Letter Formalizes REMS Standardization Schedule

Sep 01 2011

Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Oct 11 2011

Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?

Oct 24 2011

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program

Jul 16 2016

Related Companies

Santhera Pharmaceuticals

Additional Topics

United States Policy Regulation Review Pathway Drug Review

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window